Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically indicated for reducing the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by inhibiting the protease-activated receptor-1 (PAR-1), which plays a key role in platelet activation and clot formation. This targeted action helps to prevent the formation of new blood clots without significantly increasing the risk of bleeding, making it a valuable option for patients who are at high risk of recurrent cardiovascular events. It is often prescribed in combination with other antiplatelet therapies, such as aspirin and clopidogrel, to enhance its efficacy. However, careful patient selection is crucial due to the potential risk of bleeding, particularly in individuals with a history of stroke or transient ischemic attack.